FATE
Fate Therapeutics Inc
Price:  
3.52 
USD
Volume:  
1,257,549.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

FATE EV/EBITDA

-467.1%
Upside

As of 2024-05-28, the EV/EBITDA ratio of Fate Therapeutics Inc (FATE) is -1.48. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. FATE's latest enterprise value is 279.36 mil USD. FATE's TTM EBITDA according to its financial statements is -188.20 mil USD. Dividing these 2 quantities gives us the above FATE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 13.9x - 23.5x 18.5x
Forward P/E multiples 20.6x - 23.1x 21.6x
Fair Price (21.98) - 3.86 (12.92)
Upside -724.5% - 9.7% -467.1%
3.52 USD
Stock Price
(12.92) USD
Fair Price

FATE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-28 -1.51
2024-05-24 -1.48
2024-05-23 -1.43
2024-05-22 -1.56
2024-05-21 -1.59
2024-05-20 -1.72
2024-05-17 -1.71
2024-05-16 -1.86
2024-05-15 -1.92
2024-05-14 -1.91
2024-05-13 -1.87
2024-05-10 -1.82
2024-05-09 -1.71
2024-05-08 -1.59
2024-05-07 -1.70
2024-05-06 -1.91
2024-05-03 -1.81
2024-05-02 -1.84
2024-05-01 -1.83
2024-04-30 -1.74
2024-04-29 -1.80
2024-04-26 -1.65
2024-04-25 -1.70
2024-04-24 -1.96
2024-04-23 -2.10
2024-04-22 -2.25
2024-04-19 -2.25
2024-04-18 -2.40
2024-04-17 -2.54
2024-04-16 -2.61
2024-04-15 -2.77
2024-04-12 -2.85
2024-04-11 -2.95
2024-04-10 -3.15
2024-04-09 -3.44
2024-04-08 -3.41
2024-04-05 -3.54
2024-04-04 -3.57
2024-04-03 -3.60
2024-04-02 -3.47
2024-04-01 -3.64
2024-03-28 -3.79
2024-03-27 -3.79
2024-03-26 -3.50
2024-03-25 -3.51
2024-03-22 -3.35
2024-03-21 -3.85
2024-03-20 -3.85
2024-03-19 -3.59
2024-03-18 -3.61